News Release

CereScan's latest patent for its neuroimaging database now covers all brain activity measurements

The company's advanced healthcare analytics ecosystem, CereMetrix®, can provide radiologists, practitioners and researchers with precise data about their patient's brain health in minutes

Business Announcement


CereMetrix Logo

image: CereMetrix Logo. view more 

Credit: © CereScan Corp.

In response to an application filed with the United States Patent and Trademark Office, CereScan® has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix®, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders. Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity. The patent expands CereScan's intellectual property and use of its wholly owned data warehouse, known to be the most comprehensive store of functional brain imaging data, associated patient demographic, clinical information and biomarkers worldwide.

"CereScan® is transforming the future of advanced brain diagnostics and use of intelligent learning to benefit those suffering from and studying complex brain disorders," said John Kelley, CEO and Chairman of CereScan®. "The expansion of our patent allows us to apply key learnings to all manners of brain measurement, and vastly expands the potential for advancements in brain science using technology."

Headquartered in Denver, CereScan® uses its patented methods, combining patient-clinical information, functional brain imaging and advanced processing software to help medical professionals identify abnormal brain physiology and activity using correlative data and pattern matching contained within its extensive data warehouse. Through the application of technology to traditional medical practice, CereScan® has assumed a leadership role in advancing precision brain diagnostics and science. Its first patent was awarded in September of 2014, and allowed for exclusive utilization of it systems and methods under more limited claims.

CereScan® is uniquely positioned to capitalize on a planned release of CereMetrix®, its MAaS (Medical Analytics as a Service) platform in 2017. Its patented technology is considered by industry insiders to be a positive disruptor in the field of diagnostic radiology. CereScan's MAaS product suite incorporated into its CereMetrix® offering is being labeled as revolutionary, based on early feedback from Radiologists, Neurologists, and Psychiatrists who have had a chance to experiment with early release versions.


About CereScan®

CereScan® combines state-of-the-art brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides unbiased evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit Connect with CereScan on Twitter @CereScan and on Facebook at

About CereMetrix®

CereMetrix® is an advanced healthcare analytics ecosystem that provides radiologists, practitioners and researchers with precise data about their patient's brain health. Each new patient's data will be compared to a library of patients with similar brain patterns, medical histories, and clinical symptoms. The unique brain diagnostic system and ever-expanding data warehouse includes over 7,000 scan encounters, including patients' medical histories, family histories, symptoms, prior treatments, incoming diagnoses, outgoing diagnoses, and brain scans, among other data points. Each scan is composed of over 262,000 data points that measure activity levels in up to 160 brain regions derived from comparisons to normative data.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.